October 28, 2011 ·
Leave a comment
Thought Leader Select is pleased to announce a pair of projects in support of a top 10 global biopharmaceutical company as it seeks to develop a portfolio of medicines in women’s health.
For the assessments, Thought Leader Select will study key opinion leaders and medical centers of excellence in the treatment of cancers affecting the gynecological health of women, specifically ovarian cancer, cervical cancer, and uterine cancer. In the first assessment, the company will identify and profile Canadian oncologists with vast expertise in research and treatment of these cancers affecting women. In the second assessment, Thought Leader Select will identify and profile Canadian medical centers with specialized infrastructures for research and treatment in these disease areas.
“We are very proud to begin this critical work supporting pharmaceutical development in the area of women’s health,” stated Neil Mellor, Thought Leader Select’s global business development consultant. “This client is an established leader in developing medicines for the treatment of various forms of cancer, and we appreciate the opportunity to help them partner with the right key opinion leaders and centers of excellence in women’s health and oncology, to ultimately help patients suffering from these cancers.”
October 21, 2011 ·
Leave a comment
Thought Leader Select announces the delivery of a multi-specialty key opinion leader assessment in aging. The firm, based in Chapel Hill, North Carolina, was retained by a top 10 global pharmaceutical company to assess the skills and experiences of physicians specializing in the treatment of the following diseases and conditions that primarily affect the over-65 population:
• Chronic Pain
• Alzheimer’s Disease
• Parkinson’s Disease
The company will be collaborating with a host of medical experts to gain further development of a portfolio of new medicines in these areas. Thought Leader Select has identified key opinion leaders in each of these areas in order to reach a roster of 100 U.S. key opinion leaders in diseases and conditions affecting the senior population.
“We are very pleased that this company has chosen to work with us on this fascinating project,” stated Neil Mellor, Thought Leader Select’s global business development consultant. “They chose us because they wanted to do two things—work with skilled physicians who have high quality, relevant experience in treating the aging population in the U.S., and they wanted to do that in the most compliant manner possible. Our validated, objective methodology, in-depth profiling, ensures that they will be working with the right physicians at the right times for the right reasons.”
October 14, 2011 ·
Leave a comment
Industry Insights from Paul Meade, M. Sc, MPH
The Sunshine Act is on the horizon, and all we know for certain is that things will be different. Will the changes be good, bad, or ugly for healthcare and the biopharmaceutical industry? Well, a bit of all three. But it is a bit like the Y2K scare, or the coming of the end of the world in December 2012 predicted by the Mayans—people in healthcare and biopharma are on alert, and no one really knows for certain how this will all play out.
Let’s start with the good, since there will be greater transparency in the interactions between manufacturers and physicians. The intended outcomes will be greater standards of remuneration for services rendered by healthcare professionals to various manufacturers, some defined threshold limit of activities (type and quantity) deemed permissible by institutions for their affiliated physicians, and a greater sense of awareness of the interactions between healthcare professionals and manufacturers, presumably by a concerned public.
With regard to the first outcome, it is hoped that some kind of industry standard for Fair Market Value will be established for the activities physicians are often engaged in when dealing with manufacturers. It will likely serve to “level the playing field,” so some manufacturers will not pay excessively for a given activity, such as consultative services. As ... read more »